OKUR ONKURE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ONKURE THERAPEUTICS INC reported revenue of n/a, net income of −$15.3M and diluted EPS of −$0.31; for the fiscal year ended December 2025 revenue was n/a.
OKUR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$63.0M, net income −$59.5M (margin n/a), EPS −$4.40
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$54.4M, net income −$52.7M (margin n/a), EPS −$15.28
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$36.9M, net income −$35.3M (margin n/a), EPS −$124.41
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$53.8M, net income −$52.0M (margin n/a), EPS −$2.12
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$39.8M, net income −$39.8M (margin n/a), EPS −$2.19
OKUR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$15.3M, EPS −$0.31
- Quarter ended Mar 31, 2026: revenue n/a, net income −$15.2M, EPS −$1.11
- Quarter ended Dec 31, 2025: revenue n/a, net income −$13.5M, EPS −$0.98
- Quarter ended Sep 30, 2025: revenue n/a, net income −$14.7M, EPS −$1.09
- Quarter ended Jun 30, 2025: revenue n/a, net income −$15.4M, EPS −$1.14
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.9M, EPS −$1.19
- Quarter ended Dec 31, 2024: revenue n/a, net income −$17.4M, EPS $96.46
- Quarter ended Sep 30, 2024: revenue n/a, net income −$11.6M, EPS −$36.55
- Quarter ended Jun 30, 2024: revenue n/a, net income −$14.1M, EPS −$44.82
- Quarter ended Mar 31, 2024: revenue n/a, net income −$9.54M, EPS −$30.37
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $18.5M, EPS −$117.48
- Quarter ended Sep 30, 2023: revenue n/a, net income −$19.2M, EPS −$5.68
- Quarter ended Jun 30, 2023: revenue n/a, net income −$19.5M, EPS −$0.65
- Quarter ended Mar 31, 2023: revenue n/a, net income −$15.1M, EPS −$0.60
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$13.6M, EPS −$0.56
- Quarter ended Sep 30, 2022: revenue n/a, net income −$13.0M, EPS −$0.53
- Quarter ended Jun 30, 2022: revenue n/a, net income −$12.3M, EPS −$0.50
- Quarter ended Mar 31, 2022: revenue n/a, net income −$13.0M, EPS −$0.53
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$10.6M, EPS $2.24
- Quarter ended Sep 30, 2021: revenue n/a, net income −$12.7M, EPS −$0.52
OKUR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$51.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$51.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$34.5M, share buybacks $4.40M
- Fiscal year ended Dec 2022: operating cash flow −$47.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$38.0M, share buybacks n/a
OKUR balance sheet
- Jun 30, 2026: cash $167M, total assets $179M, total liabilities $7.25M, shareholders' equity $172M
- Mar 31, 2026: cash $192M, total assets $199M, total liabilities $14.3M, shareholders' equity $184M
- Dec 31, 2025: cash $59.1M, total assets $62.1M, total liabilities $5.93M, shareholders' equity $56.2M
- Sep 30, 2025: cash $70.3M, total assets $72.8M, total liabilities $6.41M, shareholders' equity $66.4M
- Jun 30, 2025: cash $83.4M, total assets $86.1M, total liabilities $7.90M, shareholders' equity $78.2M
- Mar 31, 2025: cash $96.7M, total assets $99.9M, total liabilities $9.23M, shareholders' equity $90.6M
- Dec 31, 2024: cash $111M, total assets $115M, total liabilities $11.1M, shareholders' equity $104M
- Sep 30, 2024: cash $60.7M, total assets $77.6M, total liabilities $3.63M, shareholders' equity −$135M
Is OKUR profitable?
No. ONKURE THERAPEUTICS INC lost $58.7M over the last four quarters.
What is OKUR's EPS?
Diluted earnings per share over the last four quarters were −$3.49; −$0.31 in the latest quarter.